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Abstract
Spinal muscular atrophy (SMA) is a major neurodegenerative disorder of children and infants. SMA is
primarily caused by low levels of SMN protein owing to deletions or mutations of the SMN1 gene. SMN2, a
nearly identical copy of SMN1, fails to compensate for the loss of the production of the functional SMN
protein due to predominant skipping of exon 7. Several compounds, including antisense oligonucleotides
(ASOs) that elevate SMN protein from SMN2 hold the promise for treatment. An ASO-based drug currently
under Phase III clinical trial employs intronic splicing silencer N1 (ISS-N1) as its target. Cumulative studies
on ISS-N1 reveal a wealth of information with significance to the overall therapeutic development for SMA.
Here, the authors summarize the mechanistic principles behind various antisense targets currently available
for SMA therapy.
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Abstract
Spinal muscular atrophy (SMA) is a major neurodegenerative disorder of children and infants. 
SMA is primarily caused by low levels of SMN protein owing to deletions or mutations of the 
survival motor neuron 1 (SMN1) gene. SMN2, a nearly identical copy of SMN1, fails to 
compensate for the loss of the production of the functional SMN protein due to predominant 
skipping of exon 7. Several compounds, including antisense oligonucleotides (ASOs) that elevate 
SMN protein from SMN2 hold the promise for treatment. An ASO-based drug currently under 
phase 3 clinical trial employs intronic splicing silencer N1 (ISS-N1) as its target. Cumulative 
studies on the ISS-N1 reveal a wealth of information with significance to the overall therapeutic 
development for SMA. Here we summarize the mechanistic principles behind various antisense 
targets currently available for SMA therapy.
Keywords
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Genetics of spinal muscular atrophy
Spinal muscular atrophy (SMA) is a devastating genetic neurodegenerative disease of 
children and infants [1–4]. Low levels of Survival Motor Neuron (SMN) protein due to 
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deletion or mutation of SMN1 gene is a primary cause of SMA [5,6]. SMN is a 
multifunctional protein with distinct functional domains including tudor, nucleic acid 
binding, self-association, YG-box, proline-rich and calpain cleavage domains (reviewed in 
[7]). Underscoring the importance of every functional domain, point mutations throughout 
SMN have been linked to SMA [7]. A nearly identical paralog, SMN2, fails to fully 
compensate for the loss of SMN1 due to a critical C to T transition at position 6 (C6U 
transition in transcript) in exon 7 [8]. C6U leads to exon 7 skipping during pre-mRNA 
splicing of SMN2; as a consequence, a truncated highly unstable protein (SMNΔ7) is 
produced [9–12]. SMN2 can partially compensate the defects caused by the lack of SMN1 
since it (SMN2) produces low levels of full-length SMN [5,13]. Confirming the disease-
modifying role of SMN2, SMA patients with a high SMN2 copy number manifest reduced 
SMA severity [14–16]. The disease spectrum of SMA is broad and mouse models 
representing different severities have been developed [17–21]. Early manifestations captured 
in the severe mouse models of disease are motor neuron hyperexcitability and 
morphological and functional defects of peripheral neuromuscular junctions (NMJs) and 
central synaptic inputs [22–30]. Some of these SMA mouse models also capture 
accompanying defects in other tissues including heart, intestine, liver, pancreas and lung 
[30–36]. SMA severity is likely to depend upon several factors that affect SMN levels 
through transcription, splicing, translation, posttranslational modifications and protein-
protein interactions [37–44]. Factors independent of SMN could also influence the severity 
of SMA and/or cause SMA [45]. Additionally, environmental conditions, particularly 
hypoxia and oxidative stress may also increase disease severity [46,47].
Therapeutic approaches of SMA
Given the large number of potentially contributing variables (genes and environment) that 
could impact the severity of SMA, effectiveness of a specific treatment may differ among 
patients. Various approaches tested for SMA therapy in either mice or human trials include 
histone deacetylase (HDAC) inhibitors, translation read-through compounds, quinazolines, 
hydroxyurea, polypeptide- and protein-based therapies, antisense oligonucleotide (ASO)-
based therapies, gene-based therapies and stem cell-based therapies [48, reviewed in 49–55]. 
ASO-based approaches aimed at exon 7 splicing correction have employed several targets 
including the 3′ splice site (3′ ss) of exon 8 [56], element 1 (57), intronic splicing silencer 
N1 (ISS-N1) [58], GC-rich sequence (GCRS) [59], ISTL1 and ISS-N2 [60] and the 100th 
position of intron 7 (Figure 1) [61]. Among these, the largest number of studies has been 
done on ISS-N1-targeting ASOs [64], since the first report published in 2006 [58]. ISIS-
SMNRx, an ISS-N1-targeting drug, is currently in a phase 3 clinical trial [65]. If successful, 
ISIS-SMNRx will become the first ASO-based drug to elevate the levels of a fully functional 
protein by stimulating the inclusion of an exon. Selection of the target site is a key to the 
splicing modulation by an ASO. An ASO that tightly anneals to an exonic target may 
interfere with nuclear export (of mRNA) and/or block mRNA translation even if that ASO is 
highly efficient in promoting exon inclusion [64]. Hence, an effective ASO-based drug for 
SMA would likely be the one that anneals to an intronic target. Several recent reviews 
provide updates on ASO-based therapies of genetic diseases including SMA [66–68]. There 
are numerous mechanisms by which an ASO can modulate pre-mRNA splicing. These 
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include but not limited to the displacement of a transacting factor on pre-mRNA, structural 
remodeling of pre-mRNA, recruitment of novel transacting factors on pre-mRNA, 
transcriptional pausing and co-transcriptional splicing regulation. The purpose of this report 
is to furnish a brief account of mechanisms of ASO-based approaches that are being 
considered for SMA therapy. The mechanism of SMN exon 7 splicing regulation has been 
reviewed elsewhere [69].
Antisense therapy based on canonical targets
An ASO-based drug for SMA can be developed based on targets of various nature. For the 
sake of simplification we categorize antisense targets as canonical and non-canonical 
targets. A canonical target for SMA therapy is a sequence motif that imparts a strong 
negative effect on SMN2 exon 7 splicing. As per rule, deletions or mutations of a canonical 
target should promote SMN2 exon 7 inclusion. Hence, sequestration of such motif by an 
ASO should also restore SMN2 exon 7 inclusion. Among desired features of an ideal 
canonical target are positioning and accessibility as well as strength and specificity of the 
ASO:target interactions. Characteristics of an ideal ASO are aqueous solubility, high 
stability, low toxicity and an efficient means of delivery. Since a number of ASO-based 
studies have been successfully conducted employing ISS-N1 as a target, we begin by 
providing the background information on ISS-N1. The discovery of ISS-N1 was a direct 
consequence of the findings in a previous study of in vivo selection of the entire exon 7 [70]. 
The purpose of in vivo selection was to uncover the contribution (role) of every single 
position (residue) of exon 7 in inclusion/exclusion of exon 7 during pre-mRNA splicing of 
SMN1/SMN2 in a given cell type. Of note, most early studies focused on strengthening the 3′ 
ss as a possible means to induce SMN2 exon 7 inclusion, since C6U creates an inhibitory 
context very close to the 3′ ss of exon 7 [71–74]. Surprisingly, the results of in vivo 
selection revealed that the 5′ ss of exon 7 is also very weak. Indeed, a single nucleotide 
substitution that improved the 5′ ss of exon 7 resulted in SMN2 exon 7 inclusion even in the 
presence of an abrogated Tra2β1 motif that was considered to be an essential element for the 
inclusion of exon 7 in both SMN1 and SMN2 [70]. Of note, a recent in vivo study showed 
Tra2β1 dispensable for inclusion of the SMN exon 7 [75], underscoring that the one-motif-
one protein hypothesis needs revision as multiple proteins may interact with the same and/or 
overlapping motifs to modulate pre-mRNA splicing [76]. Findings of in vivo selection 
triggered the quest for novel regulatory elements that weaken and/or sequester the 5′ ss of 
SMN2 exon 7. This required a thorough analysis of cis-regulatory elements as well as 
structural elements that may affect the accessibility of the 5′ ss of exon 7. Traditionally, the 
5′ ss of a human U2-type intron is defined by the last 3 and the first 6 residues of an exon 
and an intron, respectively [77]. However, the accessibility of the 5′ ss could be modulated 
by RNA-RNA and RNA-proteins interactions involving motifs away from the 5′ ss of an 
exon [78–81].
In the context of SMN2, several overlapping deletions downstream of the 5′ ss promoted 
exon 7 inclusion [58]. The shortest of these deletions with the most prominent stimulatory 
effect on SMN2 exon 7 splicing was a 15-nt long sequence (CCAGCAUUAUGAAAG) that 
spanned the 10th through 24th positions of intron 7. This unique 15-nt-long sequence was 
named ISS-N1 (Figure 1) [58]. Underscoring the inhibitory nature of ISS-N1, its 
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sequestration by an ASO fully restored SMN2 exon 7 inclusion in SMA patient cells [58]. 
This study utilized a 2OMe ASO that is characterized by a phosphorothioate backbone and 
2′-O-methyl modifications at every position. Two key observations were significant for the 
future development of an ASO-based therapy employing ISS-N1 as a target. First, the ISS-
N1-targeting ASO produced a robust stimulatory effect on SMN2 exon 7 splicing in SMA 
patient cells even at low concentration e.g. 5 nM. Second, the antisense effect against the 
ISS-N1 target was specific to the target because ASO had no effect on splicing of SMN2 
minigene if the ISS-N1 target was mutated. At the same time, compensatory mutations 
within the ASO fully rescued its stimulatory effect in a SMN2 minigene with the mutated 
target [58]. As a consequence of these promising results, ISS-N1 became the frontrunner 
target for developing an ASO-based therapy of SMA. However, new questions pertaining to 
the role of ASO chemistry, in vivo efficacy and independent validations emerged. With the 
passing of time, an increasing number of investigators contributed to testing the efficacy of 
ISS-N1-targeting ASOs using various chemistries and different mouse models of SMA [64]. 
Findings of these studies had a transformative effect on the field (of SMA and antisense 
technology for aberrant pre-mRNA splicing correction) as several of the ISS-N1 targeting 
ASOs drastically pushed the boundaries of therapeutic efficacies known until today.
At the time when ISS-N1 was discovered at University of Massachusetts Medical School 
(Worcester, MA, USA) [58], ISIS Pharmaceuticals (Carlsbad, CA, USA) was looking to 
develop an ASO-based drug for SMA. In collaborations with the Krainer laboratory at Cold 
Spring Harbor Laboratory (New York, USA), ISIS Pharmaceuticals designed and screened 
multiple ASOs against exonic and intronic targets [82,83]. All ASOs used in these studies 
carried phosphorothioate backbone and 2′-O-methoxyethyl (MOE) modifications. Of note, 
ISIS Pharmaceuticals specializes in MOE chemistry and has produced a FDA-approved drug 
based on MOE chemistry [84]. The most effective ASO turned out to be ASO-10-27 that 
targets ISS-N1 [83]. ISIS Pharmaceuticals has procured exclusive rights to the ISS-N1 target 
to develop an antisense drug for SMA. The lead ASO (ASO-10-27) has been branded as 
ISIS-SMNRx, and is currently undergoing phase 3 clinical trial [65]. A preclinical study 
with ASO-10-27 showed unprecedented therapeutic efficacy in a severe model of SMA [85]. 
In particular, systemic treatment with two high doses (160 mg/kg bodyweight) of 
ASO-10-27 increased median survival of severe SMA mice from 10 days to 248 days. 
However, the median survival of severe SMA mice was substantially lower when ASO 
delivery (20 mg/kg bodyweight) was performed through intra-cerebroventricular (ICV) 
route. Given the charged backbone of MOE ASOs, it is likely that these molecules (MOE 
ASOs) cause toxicity in brain. Consistently, authors did not test the efficacy of higher doses 
(than 20 mg/kg bodyweight) of ASO-10-27 through ICV delivery. Nonetheless, efficacy of 
systemic administration of ASO-10-27 demonstrated for the first time that the life 
expectancy of severe SMA model could be extended more than ten-fold, surpassing all 
previous records of therapeutic efficacy of compounds hitherto tested.
Recent studies with ISS-N1-targeting morpholinos have also shown very promising results 
[86–89]. Unlike MOE ASOs, morpholino ASOs contain neutral backbone, hence, are likely 
to exert less adverse effects at high dosages upon ICV administration. Indeed, a single ICV 
administration of a 20-mer morpholino ASO increased median survival of severe SMA mice 
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from 14 days to more than 100 days (86). A subsequent study employing a single ICV 
administration of a 25-mer morpholino ASO (40 mg/kg body weight) increased lifespan of 
severe SMA mice to an unprecedented 30-fold (87). These results underscore the importance 
of ASO chemistry and size as critical factors in determining the efficacy of an ASO-based 
therapy of SMA. Findings of these in vivo studies further pushed the boundaries of 
therapeutic efficacy of compounds reported thus far for the treatment of SMA. A better 
efficacy with a single low dose (40 mg/kg body weight) of morpholino ASO compared to 
two high doses (160 mg/kg body weight) of MOE ASO undoubtedly puts morpholino 
chemistry as front runner for developing a future drug for SMA therapy.
The results of these initial studies on ISS-N1 provide important insights into the mechanism 
by which an ISS-N1-targeting ASO promotes exon 7 inclusion. For instance, the negative 
effect of ISS-N1 was partly retained in a heterologous context [58], suggesting that ISS-N1 
is a portable cis-element with a potential to recruit inhibitory factors and/or separate the 
positive cis-elements away from the 5′ ss of an exon. An independent study that confirmed 
the inhibitory nature of ISS-N1 suggested the role of two hnRNP A1/A2 motifs in 
conferring the negative effect of ISS-N1 [83]. Of note, the first residue of ISS-N1 is a 
cytosine that occupies the 10th intronic position (+10C) and does not belong to either hnRNP 
A1/A2 motifs reported in ISS-N1. Interestingly, sequestration of +10C was found to be 
absolutely critical for the stimulatory effect of an ISS-N1-targeting ASO [90]. In a 
subsequent study, it was proposed that ISS-N1 acts as a barrier between the 5′ ss of exon 7 
and the binding site of stimulatory factors TIA1/TIAR [91]. Hence, any mechanism by 
which an ASO targeting ISS-N1 produces a stimulatory effect on SMN2 exon 7 splicing 
must account for the roles of +10C and TIA1/TIAR that precede and follow the hnRNP 
A1/A2 motifs within ISS-N1, respectively. The fact that the inhibitory effect of ISS-N1 in a 
heterologous context is substantially lower than in the wild type context [58], suggests the 
role of additional inhibitory factors (proteins and RNA sequences/structures) that coordinate 
with ISS-N1 in the wild type context. Indeed, there are at least three inhibitory cis-elements 
in the vicinity of ISS-N1. The first among these is TSL2, a terminal stem-loop structure that 
sequesters the 5′ ss of exon 7 (Figures 1 and 2) [63]. The second negative element is a GC-
rich sequence (GCRS) that partially overlaps ISS-N1 [59]. The third is an internal stem 
formed by a long-distance interaction (ISTL1) in which ISS-N2, a deep intronic sequence, 
interacts with the sequences at the beginning of intron 7 (Figures 1 and 2) [60]. Hence, an 
ISS-N1-targeting ASO is likely to trigger several interconnected events including 
displacement of hnRNP A1/A2, abrogation of ISTL1 and recruitment of TIA1/TIAR 
(Figures 2 and 3) [93]. As a result, the 5′ ss of exon 7 becomes more conducive for the 
recruitment of U1 snRNP that plays a critical role in setting the stage for intron 7 removal - 
(Figure 3).
As mentioned earlier, other ASO targets used for correction of SMN2 exon 7 splicing 
include GCRS, ISS-N2 and element 1. The GCRS is an 8-nt long sequence and partially 
overlaps with ISS-N1 [59]. This is the sole GC-rich sequence in the first half of intron 7. 
Sequestration of the GCRS by an 8-mer 2OMe ASO (3UP8) fully restored SMN2 exon 7 
inclusion in SMA patient cells [59]. There is a parallel between mechanisms of ISS-N1- and 
GCRS-targeting ASOs. In both cases, ISTL1 is abrogated due to sequestration of 10C 
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(Figure 2). This in turn brings structural changes conducive for the recruitment of U1 snRNP 
at the 5′ ss of exon 7 (Figure 3). An improved version of 3UP8 (3UP8i) with terminal 
modifications showed promising results in two mouse models of SMA (94). Unlike ISS-N1 
and the GCRS, ISS-N2 is located away from the 5′ ss of exon 7 and yet communicates with 
the 5′ ss through ISTL1 (Figures 1B and 3) [60]. A 15-mer ISS-N2-targeting 2OMe ASO 
(ASO 283–297) stimulated SMN2 exon 7 inclusion in SMA patient cells [60]. The 
mechanism by which the ISS-N2-targeting ASO promotes SMN2 exon 7 inclusion involves 
the disruption of ISTL1 and possibly other structural changes conducive for the recruitment 
of U1 snRNP at the 5′ ss of exon 7 [93]. Element 1 is a poorly characterized long inhibitory 
element within intron 6. The first study with a 16-mer element 1-targeting 2OMe ASO 
(oligo-element1) produced a moderate stimulatory effect on exon 7 splicing in the context of 
a minigene [57]. Recently, a 26-mer element 1-targeting morpholino ASO (E1MO-ASO) has 
shown promising results in a mouse model of SMA [95]. The mechanism by which element 
1-targeting ASOs stimulate SMN2 exon 7 inclusion may involve displacement of negative 
factors leading to the remodeling of the 3′ ss of exon 7.
Antisense therapy based on splice site suppression
Considering that skipping of SMN2 exon 7 is caused by pairing of the 5′ ss of exon 6 with 
the 3′ ss of exon 8, sequestration of the 3′ ss of exon 8 will likely prevent or delay this 
pairing. In addition, , sequestration of the 3′ ss of exon 8 may force the inclusion of exon 7 
by pairing of the 5′ ss of exon 6 with the 3′ ss of exon 7. In this case intron 7 will be retained 
due to unavailability of the 3′ ss of exon 8. Considering exon 7 is the last coding exon, 
SMN2 mRNA transcript with retained intron 7 will theoretically be able to make the full 
length SMN. However, this outcome is conditional: the intron 7-contianing mRNA should 
be efficiently exported from the nucleus. Moreover, the translation of this transcript, which 
now has the newly-acquired long 3′ untranslated region (3′UTR), should not be blocked by 
microRNAs. Of note, a transcript with novel 3′UTR may perturb the expression of several 
proteins by titrating away microRNAs from their corresponding mRNAs [96]. An early 
study employed 2OMe ASO (OligoJNCT) to block the 3′ ss of exon 8 and tested the effect on 
exon 7 splicing [56]. While OligoJNCT did not completely prevent exon 7 skipping, it did 
increase the levels of exon 7 included transcripts with or without intron 7 retention. The fact 
that the removal of intron 7 is not mechanistically possible if the 3′ ss of exon 8 is 
sequestered, it is likely that OligoJNCT promoted intron 7 removal by binding to other 
targets. A subsequent study used a vector-based expression of ASOs sequestering the 3′ ss 
of exon 8 [97]. Several ASOs that sequestered the junction of intron 7 and exon 8 showed a 
reduction in the levels of SMN2 exon 7 skipped transcripts accompanied by an increase in 
the levels of SMN in HeLa cells. A similar approach produced increased levels of full-length 
SMN2 transcripts in SMA patient cells in which an ASO targeting the 3′ ss of SMN2 exon 8 
was expressed in the context of U7 snRNP, which protects against hydrolysis by 
ribonucleases [98]. However, since intron 7-retained products were not detected, it is likely 
that the ASO is working through additional mechanisms other than the expected 
sequestration of the 3′ ss of SMN2 exon 8.
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Bifunctional ASOs for SMA therapy
A bifunctional ASO is comprised of two distinct sequence motifs i.e. antisense and tail 
motifs. The antisense motif is the complementary sequence against a predetermined target 
site; whereas, the tail motif is a hanging sequence that interacts with and/or recruits splicing 
factor(s). Early studies on bifunctional ASOs conducted more than a decade ago were aimed 
at delivering positive splicing factors to the 3′ ss of exon 7 [71,72]. A recent more 
systematic study compared the efficacy of multiple bifunctional ASOs targeting SMN2 exon 
7 in vitro as well as in patient cells [99]. This study also examined the impact of 
oligonucleotide modifications on the efficacy of bifunctional ASOs. A complex pattern 
emerged with respect to the efficacy of these ASOs. A 38-nt bifunctional ASO, 
oligonucleotide 1, carrying a 23-nt unmodified tail and a 15-nt 2OMe antisense motif that 
annealed from the 2nd to 16th positions of exon 7 turned out to be the most effective 
bifunctional ASO based on both in vitro and cell-based assays [99]. Oligonucleotide 1 
retained its stimulatory effect even when the annealing position was shifted to exon 6. The 
23-nt unmodified tail in oligonucleotide 1 is comprised of three AGGAGG motifs separated 
by C residues. Notably, modifications of the sugar-phosphate backbone in the tail motif of 
oligonucleotide 1 were less effective. This could be due to perturbations in the interface of 
RNA-protein interactions. The Authors hypothesized that the stimulatory effect of 
oligonucleotide 1 is due to interaction of the tail sequence with Tra2β and Tra2β-interacting 
proteins. A more recent study showed that the tail motif of oligonucleotide 1 interacts with 
several proteins; some of these interactions result in various types of nonproductive 
complexes [100]. This explains why a very high concentration (250 nM) of oligonucleotide 
1 is required to observe the maximum efficacy [99]. As a substitute to the delivery of high 
concentrations of bifunctional ASOs, continuous expression of exon 7-targeting bifunctional 
ASOs employing vector-based approaches has been examined [101–103]. Significantly, 
expression of an U7 snRNP-derived bifunctional ASO targeting SMN2 exon 7 produced 
~20-fold increase in the life expectancy of a severe mouse model of SMA and improved 
neuromuscular junction properties [102,103]. This suggests that high concentrations of 
transacting factors, including components of U7 snRNP in the vicinity of exon 7, have the 
potential to modulate disease severity. Bifunctional ASOs targeting the 3′ ss of SMN2 exon 
8 [104,105], element 1 within SMN2 intron 6 [106] and ISS-N1 within SMN2 intron 7 have 
also been employed [107]. However, the results of these experiments were somewhat less 
impressive due to relatively low efficacy in vivo. One of the disadvantages of bifunctional 
ASOs is the permanent entrapment of one or more transacting factor(s). This may produce 
unintended negative consequences on cellular metabolism, as entrapped factors may not be 
available for their designated functions. Further, due to its large size, a bifunctional ASO 
may be more likely to produce off-target effects through annealing to the partially 
complementary sequences. Supporting this argument, none of the bifunctional ASOs 
reported thus far have an efficacy comparable to that of the MOE or morpholino ASO that 
targets ISS-N1.
Dual-masking ASOs for SMA therapy
Dual-masking and double targeting refers to simultaneous sequestration of two distinct 
targets within a pre-mRNA. However, unlike double targeting in which two different ASOs 
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simultaneously target two distinct sites, dual-masking employs a single ASO molecule to 
simultaneously target two distinct sites. Studies with double targeting 2OMe ASOs and U7 
snRNP-associated ASOs did not provide any significant benefits in splicing correction 
[61,97]. Recently, several dual-masking 2OMe ASOs have been evaluated by targeting two 
of the four known inhibitory cis-elements [61]. These cis-elements are: element 1, ISS-N1, 
+100G (the 100th position of intron 7) and the 3′ ss of exon 8 (Figure 1A). The most 
promising result was obtained by Dual-1, a 39-nt ASO that simultaneously sequestered ISS-
N1 and the 3′ ss of exon 8. The annealing position of Dual-1 spanned from 9th to 29th 
positions of intron 7 and from −13th to +5th position of exon 8 (Figure 4). Similar to an ISS-
N1-targeting ASO, Dual-1 is predicted to displace hnRNP A1/A2, abrogate ISTL1, and 
recruit TIA1/TIAR at the 5′ ss of exon 7. In addition, Dual-1 brings the 5′ ss and 3′ ss of 
intron 7 in close proximity (Figure 4). Such an outcome would favor an intron definition 
model as a mechanism to promote SMN2 exon 7 inclusion [69]. Consistent with the strong 
stimulatory effect on SMN2 exon 7 splicing, Dual-1 substantially elevated the levels of SMN 
in SMA patient cells [61]. The results were more promising at the highest tested 
concentration of 200 nM. Unlike bifunctional ASOs, dual-masking ASOs do not require a 
transacting factor for their function. The efficacy of Dual-1 appears to exceed all chemically 
synthesized bifunctional ASOs reported thus far. However, it remains to be determined if a 
dual-masking ASO retains its efficacy in vivo.
Future perspective
Approaches to correct SMN2 exon 7 splicing employing ASO-based strategies have come a 
long way. While early in vitro and cell-based studies were aimed at testing the proof of 
principles, subsequent in vivo studies have furnished promising results with great 
significance to therapy. A series of seminal discoveries employing the ISS-N1 target 
provides a roadmap for future pre-clinical studies with other ASOs. The most valuable and 
rather fortunate lesson learnt from the ISS-N1 target is the reproducibility of results in 
different laboratories in different mouse models employing different oligonucleotide 
chemistries. Unfortunately, it is not always the case that major claims of one laboratory are 
reproducible in another laboratory [108–110]. The healthy tradition of independent 
validation is key to propel discoveries from basic laboratory studies to clinical trials. As the 
list of therapeutic compounds for the treatment of SMA grows, the need for independent 
validation has never been greater. This is particularly true for proprietary compounds that 
are not commercially accessible and/or remain very expensive to synthesize. In any 
scenario, there are hurdles in realizing acceptable clinical outcomes based on the otherwise 
promising results of cell- and/or animal-based studies. A key fact to reconcile is that not all 
ASO-based approaches are analogous even when the same target is used. For instance, a 
single dose of a synthetic ASO will likely produce a different outcome than the continuous 
expression of the same ASO employing a vector. In many respects, vector-based delivery of 
an ASO is analogous to gene therapy that promises full-length SMN by continuous supply 
of transcripts from the exogenously delivered gene. Hence, it is unlikely that a vector-based 
delivery of an ASO will translate into therapy until the advantages of this approach over 
gene therapy are clearly demonstrated. Nonetheless, vector-based delivery remains an 
important tool to assess the impact of the sustained expression of an oligonucleotide or a 
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transacting factor on disease severity in a mouse model of SMA. These same considerations 
for SMA therapy development also apply to any other disease.
One of the attractive aspects of therapy based on a chemically synthesized ASO is the 
potential for replacement of today’s working ASO with tomorrow’s improved ASO as the 
technology becomes advanced. While success of ISIS-SMNRx will not be known for 
sometime, there is a need for additional targets so that other oligonucleotides and 
chemistries could be employed for SMA therapy. There is no universal rule with respect to 
the size of an ASO for in vivo application. Large and small ASOs carry their own 
advantages and disadvantages. A large ASO has disadvantages of: (i) self sequestering by 
folding into secondary and high-order structures, (ii) forming non-productive complexes by 
interacting with cellular proteins, and (iii) producing off-target effects due to high tolerance 
for mismatch base pairing. A small ASO has disadvantages of: (i) being diluted by 
interactions with multiple probable targets in the genome/transcriptome, and (ii) having fast 
clearance in the blood. However, there are several advantages unique to a small ASO. Most 
important among these are the low cost of synthesis, low tolerance for mismatch base 
pairing and easier transport across biological barriers. The low tolerance for the mismatch 
base pairs results into the low off-target effects and a high specificity for the target. 
Furthermore, a small ASO offers feasibility of synthesis of a large number of variants with 
different modifications at every single position of the oligonucleotide. Of note, the potential 
of ASO-based therapy remains grossly underutilized due to the lack of studies on 
optimization of modifications at every position of an oligonucleotide. An antisense 
compound should be treated no different than a small molecule in which a single 
modification could bring desirable features such as improved stability, high specificity and 
reduced toxicity. Indeed, terminal modifications of the 8-mer-2OMe ASO targeting the 
GCRS turned out to be critical for in vivo efficacy [94]. One of the major hurdles of an 
ASO-based therapy for neurodegenerative diseases is the inability of an ASO to cross blood 
brain barrier. Any breakthrough in this direction would have a transformative impact for the 
treatment of these diseases.
Success of an ASO-based therapy in SMA has implications for the treatment of other 
genetic diseases requiring a splicing correction. Progress thus far has been very bright and 
the future of an ASO-based therapy for SMA looks even brighter. An ASO-based approach 
described here will potentially benefit all sub-types of SMA patients affected by the loss of 
SMN1. For a wide application of an ASO-based approach, modalities of time, dose and 
method of delivery will have to be worked for different patient groups. A combination 
therapy with ASO-based approach as one of the main ingredients of the treatment may 
provide a better outcome. However, compatibility of other ingredient(s) in combination 
therapy remains a matter of future investigation.
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Spinal 
muscular 
atrophy
Spinal muscular atrophy (SMA) is the leading genetic cause of infant 
mortality.
SMN SMN is a multifunctional protein with distinct functional domains 
including tudor, nucleic acid binding, self-association, YG-box, 
proline-rich and calpain cleavage domains.
Key terms for “Therapeutic approaches of SMA”
Antisense 
oligonucleotide
Antisense oligonucleotides (ASOs) are nucleic acid molecules that 
anneal to specific RNA or DNA sequences. ASOs have been used to 
block regulatory sequences to modulate alternative pre-mRNA 
splicing.
ISS-N1 ISS-N1 is a 15-nt long intronic splicing silencer located from the 
10th to 24th position of SMN intron 7. ISS-N1 is the leading target 
for an ASO-mediated splicing correction in SMA.
ISIS-SMNRx ISIS-SMNRx is an ASO-based drug currently undergoing phase 3 
clinical trial for the treatment of SMA. Drug is based on proprietary 
MOE chemistry of ISIS Pharmaceuticals and targets ISS-N1 
sequence within SMN2 intron 7.
Key terms for “Antisense therapy based on canonical targets”
GCRS GCRS is an 8-nt long intronic splicing silencer located from the 7th to 14th 
position of SMN intron 7. GCRS is the smallest validated target for an ASO-
mediated splicing correction in SMA.
ISS-N2 ISS-N2 is a 23-nt long deep intronic sequence located from the 275th to 297th 
position of SMN intron 7. ISS-N2 is a recently validated target for an ASO-
mediated splicing correction in SMA.
Element 1 Element 1 is a long inhibitory cis-element within SMN intron 6.
Key terms for “Antisense therapy based on splice site suppression”
U7 snRNP 
derived 
ASOs
U7 snRNP is a RNA-protein complex involved in the 3′ end maturation of 
histone pre-mRNAs. The RNA component of U7 snRNP could be modified 
to include antisense sequence for splicing modulation. Targeting of exon 7 
or the 3′ ss of exon 8 by ASOs expressed in the context of the U7 snRNP 
promote SMN2 exon 7 inclusion.
Key terms for “bifunctional ASOs for SMA therapy”
Bifunctional 
ASO
A bifunctional ASO is comprised of two distinct sequence motifs i.e. 
antisense and tail motifs. The antisense motif anneals to a 
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predetermined target site within SMN2 pre-mRNA and the tail motif 
recruits splicing factor(s) for stimulation of SMN2 exon 7 inclusion.
Key terms for “Dual-masking ASOs for SMA therapy”
Dual-masking 
ASO
A dual-masking ASO simultaneously sequesters two distinct sites 
within SMN2 pre-mRNA.
Dual-1 Dual-1 is a 39-nt long ASO that simultaneously sequestered ISS-N1 
and the 3′ ss of exon 8.
Key terms for “Future perspective”
Independent validation Independent validation is a critical to propel discoveries 
from basic laboratories to clinical trials.
Position-specific 
optimization of an 
oligonucleotide
Optimization of modifications at every position of an 
oligonucleotide is key to improve the efficacy of a 
therapeutic ASO.
Singh et al. Page 17
Future Med Chem. Author manuscript; available in PMC 2016 September 18.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Executive summary
Genetics of spinal muscular atrophy
▪ Low levels of the multifunctional SMN protein primarily due to deletion or 
mutations of SMN1 cause SMA, the leading genetic cause of infant death.
▪ SMN2, a nearly identical copy of SMN1, cannot fully compensate for the 
SMN1 loss due to predominant skipping of SMN2 exon 7, leading to the 
production of SMNΔ7, a truncated protein that is rapidly degraded.
▪ Defects caused by the lack of SMN1 can be partially compensated by the 
presence of SMN2, which produces low levels of full-length SMN.
▪ Severity of SMA is likely to depend upon several factors that regulate SMN 
levels through transcription, splicing, translation, posttranslational 
modifications and protein-protein interactions.
▪ Factors independent of SMN could also affect the severity of SMA and/or 
cause SMA.
ASO-based therapy of SMA
▪ A canonical ASO-based therapy of SMA is based on promoting SMN2 exon 
7 inclusion by an oligonucleotide that binds to a specific sequence (target) 
within SMN2 pre-mRNA.
▪ Potential targets of an ASO-based therapy of SMA include the 3′ ss of exon 
8, element 1, ISS-N1, GCRS, ISTL1, ISS-N2 and the 100th position of SMN2 
intron 7.
▪ Stimulatory effect of an ASO could be due to displacement of a negative 
regulator, recruitment of a positive regulator and formation of a favorable 
RNA structure.
▪ ASOs annealing to sequences away from the SMN2 specific mutations (C6U 
and A+100G) could have dramatic effects on exon 7 splicing.
Highlights of ISS-N1 target under clinical trial
▪ Located close to the 5′ ss of exon 7, the 15-nt long ISS-N1 is a strong 
negative regulator of SMN2 exon 7 splicing.
▪ ISS-N1 harbors two putative binding sites for inhibitory factor hnRNP 
A1/A2.
▪ The first position of ISS-N1 is a cytosine residue that participates in a unique 
RNA structure formed by a long-distance interaction.
▪ ISS-N1 suppresses accessibility of the 5′ ss of exon 7.
▪ ISS-N1 is the leading target for an ASO-based therapy of SMA.
▪ A series of independent studies carried in different mouse models of SMA 
validates the therapeutic efficacy of ISS-N1-targeting ASOs
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▪ ISIS-SMNRx, an ISS-N1-targeting drug, is currently undergoing phase 3 
clinical trial. If successful, ISIS-SMNRx will become the first ASO-based 
drug to elevate the levels of a fully functional protein by stimulating the 
inclusion of an exon.
GCRS target for splicing correction by a small ASO
▪ The 8-nt long GCRS is a negative regulator of SMN2 exon 7 splicing.
▪ GCRS is the only known target for an ASO-mediated splicing correction by a 
small ASO.
▪ Cell-based and in vivo studies validate the therapeutic efficacy of an 8-mer 
ASO targeting GCRS.
Bifunctional ASOs for splicing correction in SMA
▪ A bifunctional ASO anneals to a specific location within SMN2 pre-mRNA 
and recruits splicing factor(s) to promote exon 7 inclusion.
▪ A vector-based expression of a U7 snRNP containing bifunctional ASO has 
been found to dramatically reduce the phenotype severity of a mouse model 
of SMA.
Dual-masking ASOs for splicing correction in SMA
▪ A single molecule of a dual-masking ASO simultaneously sequesters two 
negative cis-elements on SMN2 pre-mRNA to promote exon 7 inclusion.
▪ Simultaneous sequestration of ISS-N1 and the 3′ ss of exon 8 by a dual-
masking ASO produced a better splicing correction efficacy than an ASO 
that targets ISS-N1 alone.
Future perspective
▪ Availability of other novel targets offer the potential for developing 
additional ASO-based therapies for SMA.
▪ There is a need to exploit the benefits of modification of every single position 
of an ASO.
▪ Development of an ASO capable of crossing blood brain barrier would have 
a transformative impact for the treatment of neurodegenerative diseases.
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Figure 1. Targets of SMA therapy
(A) Relative position of major targets for an ASO-mediated splicing correction in SMA. 
Neutral and positive numbering start from the first positions of exon 7 and intron 7, 
respectively. Negative numbering starts from the last position of intron 6. Element 1 
occupies positions from −68 to −112 in intron 6 [57]. ISS-N1 and GCRS occupy positions 
from +10 to +24 [58] and from +7 to +14 [59] in intron 7, respectively. 5′ISTL1 and 
3′ISTL1 refer to the 5′ and 3′ strands of ISTL1, respectively [60]. An ASO-based approach 
has been used to target the 100th position of intron 7 [61]. A+100G refers to an SMN2 
specific mutation at the 100th position of intron 7 [62]. TSL2 is an inhibitory stem-loop 
structure that sequesters the 5′ ss of exon 7 [63]. (B) Relative location of cis-elements in the 
context of the RNA secondary structure of exon 7 and intron 7. Numbering is the same as in 
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panel A. Presented structures of exon 7 and intron 7 were deduced from enzymatic and 
chemical structure probing [60,63].
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Figure 2. Effect of ISS-N1 and GCRS-targeting ASOs on accessibility of the 5′ ss of exon
The SMN2 mRNA is numbered from the start of exon 7 (neutral numbers) and the start of 
intron 7 (positive numbers) with a rainbow scheme ranging from blue to red in the 5′ to 3′ 
direction for the cartoon depiction of the phosphate backbone in the 3D models. Nucleotide 
bases in all figures are colored by type: green for adenine, blue for cytosine, orange for 
guanine and red for uracil. Secondary structures include base pairing used for model 
prediction indicated by a solid dash and additional base pairs formed during model 
calculations denoted by a tilde. All model calculations included a construct of the 5′ ss of 
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exon 7 comprising 100 nucleotides ranging from 33rd position in exon 7 to +300th position 
in intron 7 with a 225 nucleotide deletion between +57th and +283rd replaced by a three 
nucleotides to complete a UAAC tetraloop. A hierarchical stepwise assembly protocol 
within the Rosetta modeling suit (version 2015.09.57646) was used to build local secondary 
structure motifs and assemble the motifs into a tertiary model that was further refined by 
energy minimization [92]. (A) In the absence of ASO binding, the 3D model of the 5′ ss of 
exon 7 (shown on the right) was calculated with experimental base pairing restraints derived 
from SHAPE-based chemical probing of the secondary structure (shown on the left). The 
model prediction includes two stem-loop hairpin motifs, TSL2 (38th position in exon 7 to 
+2nd position in intron 7) and TSL3 (+17th to +41st positions); and two long-range stem 
interactions, ISTL1 (+3rd to +10th and +290th to +297th positions) and ISTL2 (+50th to +56th 
and +283rd to +289th positions). (B) Predicted changes in the three dimensional structure of 
the 5′ ss of exon 7 upon binding of an ISS-N1 targeting 18-mer ASO (F18) (shown on the 
right) include disruption of the TSL3 motif and ISTL1 structure. Annealing position of F18 
is marked on the secondary structure (shown left). (C) The three dimensional structure of the 
5′ ss of exon 7 upon binding of an ISS-N1 targeting 8-mer ASO (F8) (shown right) predicts 
retention of all stem-loop motifs and long-range stem interactions. Annealing position of F8 
is marked on the secondary structure (shown left). (D) Predicted changes in the three 
dimensional structure of the 5′ ss of exon 7 upon binding of a GCRS targeting 8-mer ASO 
(3UP8) (shown right) include disruption of the ISTL1 structure. Annealing position of 3UP8 
is marked on the secondary structure (shown left).
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Figure 3. Mechanism of SMN2 exon 7 splicing correction by an ISS-N1-targeting ASO
Proposed mechanism by which an ISS-N1-targeting ASO promotes exon 7 inclusion. An 
ISS-N1 targeting ASO sequesters binding sites of hnRNP A1/A2, disrupts/destabilizes 
TSL3, ISTL1 and ISTL2. This leads to binding of TIA1 to now accessible sites (shown in 
green) and enhanced recruitment of U1 snRNP to the 5′ ss of exon 7. Mechanism is adapted 
from [60]. Numbering is the same as in Figure 1A.
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Figure 4. Effect of a dual-masking ASO on accessibility of the 5′ ss of exon 7
Annealing of a dual-masking ASO (Dual-1) to ISS-N1 and the 3′ ss of exon 8 brings the 5′ 
ss of exon 7 and 3′ ss of exon 8 in close proximity. Dual-1 is described in [61]. Remaining 
structure of intron 7 is shown. Numbering is the same as in Figure 1A.
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